NHLBI Launches MAP-HEART Study to Analyze Heart Failure Phenotypes
The MAP-HEART study aims to collect and analyze biological samples from heart failure patients to identify factors affecting heart function.
Phase III
Cardiology / Heart Failure
Status
Initiated
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The MAP-HEART study is significant as it aims to identify new biomarkers and therapeutic targets in heart failure, which could reshape treatment strategies. Pharma companies should stay informed on the study's findings to leverage potential insights for drug development.
Recommended action
Humanexa recommends Monitor.
Analysis
Results from the sample analysis and any subsequent publications that may reveal new insights into heart failure mechanisms.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.